ArticleBMC infectious diseases2025
Impact of obesity on COVID-19 CoronaVac and ChAdOx1-S vaccine efficacy.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-SARS-CoV-2 nucleoprotein IgA is associated with worse disease severity in critically ill COVID-19 pneumonia patients.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
backgroundObesity significantly increases the risk of severe COVID-19 and mortality. Concerns have emerged regarding the efficacy of COVID-19 vaccines in obese populations due to potential alterations in immune responses.
methodsBetween March 2021 and March 2022, 5,071 participants with comorbidities received CoronaVac administered in two doses 28 days (± 7 days) apart and a single subsequent booster dose of ChAdOx1 with an interval of 180 days (± 30 days). Body composition was analyzed using a tetrapolar bioimpedance measurement scale. Anti-RBD IgG was dosed at baseline (D0) and on days 28, 90, 180, 270, and 360.
results1,181 participants with obesity (body fat percentage > P50), non-immune at baseline, showed significantly lower antibody titers (IgG anti-RBD) until D180 than 576 non-obese individuals. However, there was no difference in the frequency of COVID-19, COVID-19-related hospitalization or death. After the booster, no significant changes were seen. Patients with very excessive body fat (body fat percentage > P90) showed even slower seroconversion, with increased COVID-19 after D180. Similar results were observed using the routine body mass index (BMI); however, waning immunity (serology) was observed in individuals classified as having very excessive body fat only when bioimpedance was used.
conclusionParticipants with obesity demonstrated weaker and slower seroconversion, which worsened in higher body fat mass. Bioimpedance revealed quicker waning immunity, emphasizing its importance over BMI in assessing vaccine response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.